These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 21104925)
21. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Ye ZW; Camus S; Augustijns P; Annaert P Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377 [TBL] [Abstract][Full Text] [Related]
22. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346 [TBL] [Abstract][Full Text] [Related]
23. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier. van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145 [TBL] [Abstract][Full Text] [Related]
24. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Drewe J; Gutmann H; Fricker G; Török M; Beglinger C; Huwyler J Biochem Pharmacol; 1999 May; 57(10):1147-52. PubMed ID: 11230802 [TBL] [Abstract][Full Text] [Related]
25. [Pharmacological interactions with darunavir]. Moltó J; Valle M; Clotet B Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():43-50. PubMed ID: 19195459 [TBL] [Abstract][Full Text] [Related]
26. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. Mouly SJ; Paine MF; Watkins PB J Pharmacol Exp Ther; 2004 Mar; 308(3):941-8. PubMed ID: 14718607 [TBL] [Abstract][Full Text] [Related]
27. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors. Richter M; Gyémánt N; Molnár J; Hilgeroth A Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233 [TBL] [Abstract][Full Text] [Related]
28. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Hajda J; Rentsch KM; Gubler C; Steinert H; Stieger B; Fattinger K Eur J Pharm Sci; 2010 Dec; 41(5):729-35. PubMed ID: 20933082 [TBL] [Abstract][Full Text] [Related]
29. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. Holmstock N; Mols R; Annaert P; Augustijns P Drug Metab Dispos; 2010 Sep; 38(9):1407-10. PubMed ID: 20551242 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478 [TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192 [TBL] [Abstract][Full Text] [Related]
33. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. Usansky HH; Hu P; Sinko PJ Drug Metab Dispos; 2008 May; 36(5):863-9. PubMed ID: 18256206 [TBL] [Abstract][Full Text] [Related]
34. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898 [TBL] [Abstract][Full Text] [Related]
35. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Kis O; Zastre JA; Hoque MT; Walmsley SL; Bendayan R Pharm Res; 2013 Apr; 30(4):1050-64. PubMed ID: 23224979 [TBL] [Abstract][Full Text] [Related]
36. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805 [TBL] [Abstract][Full Text] [Related]
37. Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir. Luo S; Wang Z; Patel M; Khurana V; Zhu X; Pal D; Mitra AK Int J Pharm; 2011 Jul; 414(1-2):77-85. PubMed ID: 21571053 [TBL] [Abstract][Full Text] [Related]
38. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614 [TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237 [TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Huisman MT; Smit JW; Crommentuyn KM; Zelcer N; Wiltshire HR; Beijnen JH; Schinkel AH AIDS; 2002 Nov; 16(17):2295-301. PubMed ID: 12441801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]